Sort
15,273 grants matching “antimicrobial resistance”
O-polysaccharide (OPS)-IpaB Conjugate Vaccine to Prevent Shigellosis
$898,263Marcela F Pasetti · University Of Maryland Baltimore · R01 · FY2023 · AI
Innate, Transcriptomic, and Microbiomic correlates of TB infection
$898,096Michael Haggai Glickman · Weill Medical Coll Of Cornell Univ · U19 · FY2018 · AI
Evaluation of a new class of antimicrobial agents against Clostridium difficile
$897,906Saul R Tzipori · Tufts University Boston · R56 · FY2011 · AI
Novel, Non-Toxic Ocular Antiseptic For Intravitreal Injection Therapy
$897,021Stephen J Smith · Irenix Medical, Inc. · R44 · FY2021 · EY
Novel broad spectrum therapeutic glycans against Category B pathogens
$896,474David S Newburg · Massachusetts General Hospital · U01 · FY2007 · AI
A proximity ligation method to track mobile element hosts
$895,817Ivan Liachko · Phase Genomics, Inc. · R44 · FY2021 · AI
Targeting bacterial cell wall biogenesis for the development of novel antimicrob
$895,104Thomas G Bernhardt · Harvard Medical School · U19 · FY2016 · AI
[18F]fluoromannitol: A novel imaging agent to delineate osteomyelitis in sickle cell disease
$894,735Kiel Neumann · St. Jude Children'S Research Hospital · R01 · FY2025 · AI
Structure, function, and regulation of the bacterial transcription cycle
$893,989Seth A Darst · Rockefeller University · R35 · FY2021 · GM
Inducible epithelial resistance: a program investigating mechanisms to protect against acute and chronic complications of pneumonia
$893,554Scott E. Evans · University Of Tx Md Anderson Can Ctr · R35 · FY2019 · HL
Point of Care Attachment of Antibiotics onto Metal Implants
$893,372Paul T Hamilton · Affinergy ,Inc · R44 · FY2008 · AI
New Tricks for 'Old' Drugs: PK/PD of Polymyxin Nonantibiotic Combinations
$893,305Jian Li · Monash University · R01 · FY2015 · AI
Involvement Of Human Viruses Associated With Chronic Neurologic Disease
$892,913Steven Jacobson · National Institute Of Neurological Disorders And Stroke · ZIA · FY2022 · NS
Non-Modulation Phenotype and Vascular Dysfunction in Diabetes Mellitus
$892,710Gordon H Williams · Brigham And Women'S Hospital · R01 · FY2010 · HL
Ultrarapid culture-independent detection of high-priority carbepenem resistant Enterobacteriaceae directly from blood
$891,241Connie Savor Price · Denver Health And Hospital Authority · R01 · FY2019 · AI
Endolysins as tools to eradicate pneumococcal biofilms and development ofprotective immunity
$890,998Norberto Gonzalez-Juarbe · Univ Of Maryland, College Park · R01 · FY2024 · AI
Novel broad spectrum therapeutic glycans against Category B pathogens
$890,257David S Newburg · Boston College · U01 · FY2011 · AI
Lead optimization of a novel cyclic aryl-indole efflux pump inhibitor (EPI) series in combination with levofloxacin against Pseudomonas aeruginosa
$889,610Ajit K Parhi · Taxis Pharmaceuticals, Inc. · R44 · FY2025 · AI
A High Throughput Biofilm Assay System
$889,579Cristian Ionescu-Zanetti · Fluxion Biosciences, Inc. · R44 · FY2010 · GM
Molecular Antibiotic Resistance Arrays for clinical microbiology laboratories
$889,235Paul Stephen Keim · Translational Genomics Research Inst · R01 · FY2011 · AI
Non-Modulation Phenotype and Vascular Dysfunction in Diabetes Mellitus
$888,853Gordon H Williams · Brigham And Women'S Hospital · R01 · FY2009 · HL
A systems approach to manipulate microbial adaptation to structured environments
$888,728Nitin S Baliga · Institute For Systems Biology · R01 · FY2021 · AI
Targeting bacterial cell wall biogenesis for the development of novel antimicrob
$888,658Thomas G Bernhardt · Harvard Medical School · U19 · FY2015 · AI
Targeting bacterial cell wall biogenesis for the development of novel antimicrob
$888,429Thomas G Bernhardt · Harvard Medical School · U19 · FY2017 · AI
Helicobacter pylori Pathogenesis Studies
$887,010William Coleman · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2011 · DK